Jennifer E Munt, Sandra Henein, Cameron Adams, Ellen Young, Yixuan J Hou, Helen Conrad, Deanna Zhu, Stephanie Dong, Nurgun Kose, Boyd Yount, Rita M Meganck, Long Ping V Tse, Guillermina Kuan, Angel Balmaseda, Michael J Ricciardi, David I Watkins, James E Crowe, Eva Harris, Aravinda M DeSilva, Ralph S Baric
{"title":"自然DENV 3感染/疫苗接种后，同种型抗体靶向新的E糖蛋白结构域。","authors":"Jennifer E Munt, Sandra Henein, Cameron Adams, Ellen Young, Yixuan J Hou, Helen Conrad, Deanna Zhu, Stephanie Dong, Nurgun Kose, Boyd Yount, Rita M Meganck, Long Ping V Tse, Guillermina Kuan, Angel Balmaseda, Michael J Ricciardi, David I Watkins, James E Crowe, Eva Harris, Aravinda M DeSilva, Ralph S Baric","doi":"10.1016/j.chom.2023.10.004","DOIUrl":null,"url":null,"abstract":"<p><p>The envelope (E) glycoprotein is the primary target of type-specific (TS) neutralizing antibodies (nAbs) after infection with any of the four distinct dengue virus serotypes (DENV1-4). nAbs can be elicited to distinct structural E domains (EDs) I, II, or III. However, the relative contribution of these domain-specific antibodies is unclear. To identify the primary DENV3 nAb targets in sera after natural infection or vaccination, chimeric DENV1 recombinant encoding DENV3 EDI, EDII, or EDIII were generated. DENV3 EDII is the principal target of TS polyclonal nAb responses and encodes two or more neutralizing epitopes. In contrast, some were individuals vaccinated with a DENV3 monovalent vaccine-elicited serum TS nAbs targeting each ED in a subject-dependent fashion, with an emphasis on EDI and EDIII. Vaccine responses were also sensitive to DENV3 genotypic variation. This DENV1/3 panel allows the measurement of serum ED TS nAbs, revealing differences in TS nAb immunity after natural infection or vaccination.</p>","PeriodicalId":93926,"journal":{"name":"Cell host & microbe","volume":" ","pages":"1850-1865.e5"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221912/pdf/","citationCount":"0","resultStr":"{\"title\":\"Homotypic antibodies target novel E glycoprotein domains after natural DENV 3 infection/vaccination.\",\"authors\":\"Jennifer E Munt, Sandra Henein, Cameron Adams, Ellen Young, Yixuan J Hou, Helen Conrad, Deanna Zhu, Stephanie Dong, Nurgun Kose, Boyd Yount, Rita M Meganck, Long Ping V Tse, Guillermina Kuan, Angel Balmaseda, Michael J Ricciardi, David I Watkins, James E Crowe, Eva Harris, Aravinda M DeSilva, Ralph S Baric\",\"doi\":\"10.1016/j.chom.2023.10.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The envelope (E) glycoprotein is the primary target of type-specific (TS) neutralizing antibodies (nAbs) after infection with any of the four distinct dengue virus serotypes (DENV1-4). nAbs can be elicited to distinct structural E domains (EDs) I, II, or III. However, the relative contribution of these domain-specific antibodies is unclear. To identify the primary DENV3 nAb targets in sera after natural infection or vaccination, chimeric DENV1 recombinant encoding DENV3 EDI, EDII, or EDIII were generated. DENV3 EDII is the principal target of TS polyclonal nAb responses and encodes two or more neutralizing epitopes. In contrast, some were individuals vaccinated with a DENV3 monovalent vaccine-elicited serum TS nAbs targeting each ED in a subject-dependent fashion, with an emphasis on EDI and EDIII. Vaccine responses were also sensitive to DENV3 genotypic variation. This DENV1/3 panel allows the measurement of serum ED TS nAbs, revealing differences in TS nAb immunity after natural infection or vaccination.</p>\",\"PeriodicalId\":93926,\"journal\":{\"name\":\"Cell host & microbe\",\"volume\":\" \",\"pages\":\"1850-1865.e5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221912/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell host & microbe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.chom.2023.10.004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell host & microbe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.chom.2023.10.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Homotypic antibodies target novel E glycoprotein domains after natural DENV 3 infection/vaccination.
The envelope (E) glycoprotein is the primary target of type-specific (TS) neutralizing antibodies (nAbs) after infection with any of the four distinct dengue virus serotypes (DENV1-4). nAbs can be elicited to distinct structural E domains (EDs) I, II, or III. However, the relative contribution of these domain-specific antibodies is unclear. To identify the primary DENV3 nAb targets in sera after natural infection or vaccination, chimeric DENV1 recombinant encoding DENV3 EDI, EDII, or EDIII were generated. DENV3 EDII is the principal target of TS polyclonal nAb responses and encodes two or more neutralizing epitopes. In contrast, some were individuals vaccinated with a DENV3 monovalent vaccine-elicited serum TS nAbs targeting each ED in a subject-dependent fashion, with an emphasis on EDI and EDIII. Vaccine responses were also sensitive to DENV3 genotypic variation. This DENV1/3 panel allows the measurement of serum ED TS nAbs, revealing differences in TS nAb immunity after natural infection or vaccination.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
